FSD Pharma Announces Launch of IBS Clinical Study

TORONTO–(BUSINESS WIRE)–FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE)
(OTCQB: FSDDF) (FRA: 0K9) today announced the launch of a pilot clinical
study in Pittsburgh, Pennsylvania, by its strategic RD partner, SciCann
Therapeutics (“SciCann”). The study is designed to test the
safety and efficacy of SciCann’s proprietary “Steady Stomach”
cannabidiol (CBD) combination product for the treatment of irritable
bowel syndrome (IBS) patients. This study follows the previously
reported efficacy results from a preclinical study in rodent models
which demonstrated a three-fold increased efficacy in lowering abdominal
inflammation levels with the advanced combination product as

... read more at: https://www.businesswire.com/news/home/20181031005091/en/FSD-Pharma-Announces-Launch-IBS-Clinical-Study

by

Leave a Reply